Navigation Links
World Think Tank on Type 1 Diabetes Meets in Miami
Date:11/13/2007

appears to reduce disease

severity, possibly re-setting the immune system and slowing the

destruction of their insulin-producing cells.

ABOUT THE MEETINGS

The Type 1 Diabetes TrialNet Study Group

This group of type 1 diabetes experts will meet November 12-14 to discuss current and planned research around type 1 diabetes. Researchers at more than 150 medical centers in the U.S., Canada, Europe and Australia have joined this global network dedicated to study the prevention, early detection and treatment of type 1 diabetes. These centers are offering free screenings for relatives of people with type 1 diabetes, as well as clinical trials in prevention, early detection and early onset. Type 1 Diabetes TrialNet is supported by the National Institutes of Health (NIH), Juvenile Diabetes Research Foundation International, and the American Diabetes Association. To learn more about Type 1 Diabetes TrialNet, visit http://www.DiabetesTrialNet.org

The 9th International Congress of the Immunology of Diabetes Society (IDS) and American Diabetes Association (ADA) Research Symposium

International researchers will meet November 14-18 to discuss the latest science and theories in type 1 diabetes research. IDS is an international collaboration created to advance research in the etiology, pathogenesis, prevention and cure of type 1 diabetes. A key area of focus is clinical trials to alter the type 1 diabetes disease process, eventually leading to prevention of this disease. ADA's mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.

TO REGISTER FOR THE MEDIA TELECONFERENCE:

Please contact:

Sarah Bakka

sbakka@mmgct.com

301.348.1685


'/>"/>
SOURCE TrialNet
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
3. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
4. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
5. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
6. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
7. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
8. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
9. Doping technique brings nanomechanical devices into the semiconductor world
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 2Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 3Critical Step Toward Commercialization of Pre-Symptomatic Diagnosis of Ovarian Cancer Achieved by Arrayit Diagnostics 4